BU
VRTX icon

BBVA USA’s Vertex Pharmaceuticals VRTX Stock Holding History

BBVA USA’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$938K Buy
5,171
+5,144
+19,052% +$1M 0.06% 272
2021
Q2 		$5K Buy
+27
New +$5.65K ﹤0.01% 928

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBVA USA's VRTX Position: Q3 2021 in Review

BBVA USA increased its Vertex Pharmaceuticals (VRTX) stake by 19,052% in Q3 2021, buying an estimated $1M and bringing the position to 5,171 shares worth $938K. The position accounts for 0.06% of the portfolio, ranked #272.

BBVA USA first reported a position in VRTX in Q2 2021 and has held it in 2 quarters since. 933 funds tracked by Wall St. Rank hold VRTX as of Q3 2021.

  • BBVA USA held 5,171 shares of Vertex Pharmaceuticals worth $938K as of Q3 2021.
  • BBVA USA bought 5,144 Vertex Pharmaceuticals shares in Q3 2021, an estimated $1M.
  • Vertex Pharmaceuticals made up 0.06% of BBVA USA's portfolio in Q3 2021, its #272 holding.
  • BBVA USA first reported a position in Vertex Pharmaceuticals in Q2 2021 and has held it in 2 quarters since.
  • 933 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2021.

Based on BBVA USA's 13F filing for Q3 2021, filed 4 Nov 2021.